Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis.

Jung SM, Kim HS, Kim HR, Kim NY, Lee JH, Kim J, Kwok SK, Park KS, Park SH, Kim HY, Ju JH.

Int Immunopharmacol. 2014 Jul;21(1):20-5. doi: 10.1016/j.intimp.2014.04.006. Epub 2014 Apr 18.

PMID:
24752013
[PubMed - in process]
2.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

PMID:
24074008
[PubMed - indexed for MEDLINE]
Free Article
3.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

PMID:
17049139
[PubMed - indexed for MEDLINE]
Free Article
4.

Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.

Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.

Clin Exp Rheumatol. 2008 May-Jun;26(3):401-7.

PMID:
18578960
[PubMed - indexed for MEDLINE]
5.

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.

Ann Rheum Dis. 2013 Jun;72(6):895-900. doi: 10.1136/annrheumdis-2012-201338. Epub 2012 Aug 11.

PMID:
22887849
[PubMed - indexed for MEDLINE]
6.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

PMID:
17651658
[PubMed - indexed for MEDLINE]
Free Article
7.

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.

Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ.

J Med Econ. 2012;15(2):264-75. doi: 10.3111/13696998.2011.644645. Epub 2011 Dec 8.

PMID:
22115327
[PubMed - indexed for MEDLINE]
8.

The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.

Semin Arthritis Rheum. 2004 Feb;33(4):283-8.

PMID:
14978666
[PubMed - indexed for MEDLINE]
9.

Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.

Braun J, van der Heijde D.

Expert Opin Investig Drugs. 2003 Jul;12(7):1097-109. Review.

PMID:
12831346
[PubMed - indexed for MEDLINE]
10.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
[PubMed - indexed for MEDLINE]
11.

Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.

Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG.

World J Gastroenterol. 2013 Jul 21;19(27):4344-50. doi: 10.3748/wjg.v19.i27.4344. Review.

PMID:
23885145
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E.

Clin Rev Allergy Immunol. 2010 Apr;38(2-3):82-9. doi: 10.1007/s12016-009-8140-3. Review.

PMID:
19565360
[PubMed - indexed for MEDLINE]
13.

Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis.

Chen JS, Makovey J, Lassere M, Buchbinder R, March LM.

Arthritis Care Res (Hoboken). 2014 Mar;66(3):464-72. doi: 10.1002/acr.22151.

PMID:
24022870
[PubMed - indexed for MEDLINE]
14.

Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.

Moreland LW.

Pharmacoeconomics. 2004;22(2 Suppl 1):39-53. Review. Erratum in: Pharmacoeconomics. 2004;22(8):547.

PMID:
15157003
[PubMed - indexed for MEDLINE]
15.

The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.

Nell-Duxneuner V, Schroeder Y, Reichardt B, Bucsics A.

Int J Clin Pharmacol Ther. 2012 Dec;50(12):867-72. doi: 10.5414/CP201707.

PMID:
23036238
[PubMed - indexed for MEDLINE]
16.

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.

Adv Ther. 2012 Mar;29(3):234-48. doi: 10.1007/s12325-012-0007-y. Epub 2012 Mar 9.

PMID:
22411424
[PubMed - indexed for MEDLINE]
17.

Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.

Fleischmann R, Iqbal I.

Drugs Aging. 2007;24(3):239-54. Review.

PMID:
17362051
[PubMed - indexed for MEDLINE]
18.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
[PubMed - indexed for MEDLINE]
19.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.

Health Technol Assess. 2011 Mar;15(14):1-278. doi: 10.3310/hta15140. Review.

PMID:
21439251
[PubMed - indexed for MEDLINE]
Free Article
20.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Carter CT, Changolkar AK, Scott McKenzie R.

J Med Econ. 2012;15(2):332-9. doi: 10.3111/13696998.2011.649325. Epub 2012 Jan 6.

PMID:
22168788
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk